Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Macular Degeneration × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 127 Glioblastoma 84 Astrocytoma 42 Glioma 39 Neuroblastoma 36 Central Nervous System Neoplasms 36 Neoplasms 24 Neoplasm Metastasis 24 Breast Neoplasms 23 Oligodendroglioma 20 Gliosarcoma 18 Carcinoma, Non-Small-Cell Lung 18 Recurrence 12 Lymphoma, Follicular 12 Precursor Cell Lymphoblastic Leukemia-Lymphoma 11 Medulloblastoma 11 Burkitt Lymphoma 11 Meningioma 10 Lymphoma, T-Cell, Cutaneous 10 Lymphoma, Non-Hodgkin 10 Lymphoma, Mantle-Cell 10 Lymphoma, Large-Cell, Immunoblastic 10 Lymphoma, Large B-Cell, Diffuse 10 Lymphoma, B-Cell, Marginal Zone 10 Leukemia, Lymphocytic, Chronic, B-Cell 10 Hodgkin Disease 10 Testicular Neoplasms 9 Sezary Syndrome 9 Primary Myelofibrosis 9 Mycosis Fungoides 9

Interventions

brolucizumab 1 aflibercept 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡